PF-592,379 is a drug developed by
Pfizer which acts as a potent,
selective and orally active
agonist for the
dopamineD3receptor, which is under development as a potential medication for the treatment of
female sexual dysfunction and male
erectile dysfunction. Unlike some other less selective D3 agonists, a research study showed that PF-592,379 has little abuse potential in animal studies, and so was selected for further development and potentially human clinical trials.[1][2]Development has since been discontinued.[3]
^Attkins N, Betts A, Hepworth D, Heatherington AC (November 2010). "Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 40 (11): 730–42.
doi:
10.3109/00498254.2010.514961.
PMID20836725.
S2CID30288414.